4,117 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Channing Global Advisors LLC

Channing Global Advisors LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,117 shares of the company’s stock, valued at approximately $354,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Natixis Advisors LLC grew its stake in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Norman Fields Gottscho Capital Management LLC grew its stake in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Versant Capital Management Inc bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $86,000. Talbot Financial LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $4,066,000. Finally, Clear Creek Financial Management LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $450,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $83.78 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The business has a 50-day moving average price of $90.45 and a 200 day moving average price of $110.60. The firm has a market cap of $375.95 billion, a PE ratio of 25.46, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts predict that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday. They set an “equal weight” rating for the company. Finally, BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.